Biotest AG — AGM Information 2004

Jul 8, 2004

News Details

Corporate | 8 July 2004 15:56

Biotest AG: 2004 General Shareholders’ Meeting

Corporate-news announcement processed and sent by DGAP. The sender is solely responsible for the contents of this announcement. ——————————————————————————– 2004 General Shareholders’ Meeting – Biotest shareholders approve extensive capital measures Dreieich, July 8, 2004. At their General Shareholders’ Meeting in Frankfurt am Main today, the shareholders of Biotest AG authorized the Board of Management to implement extensive capital measures, including an increase in the Company’s capital stock to up to EUR 10.24 million by issuing new shares, the issuance of profit-sharing rights of up to EUR 50 million, and the purchase of treasury shares up to 10% of the capital stock. The goal of these measures is to enable the Company to react quickly and flexibly to financing needs and potential acquisitions and to strengthen the Company’s capitalization on attractive terms. Prior to this action, the shareholders of the Company, which specializes in therapeutics and diagnostic systems for clinical immunology, hematology, and intensive care medicine, approved the appropriation of the net income available for distribution and a distribution of dividends to holders of preferred shares. The latter will receive a back payment for fiscal year 2002 of EUR 0.11 per preferred share and a dividend for fiscal year 2003 in the same amount. In addition, the General Shareholders’ Meeting elected Werner Spinner as the shareholders’ representative to the Supervisory Board. Following this, the Supervisory Board confirmed Mr. Spinner as Chairman. Werner Spinner had earlier been designated a member of the Supervisory Board by the District Court in Frankfurt am Main on October 1, 2003, after the former Chairman, Dr. Hans Schleussner, resigned his office. Biotest AG The Board of Management Biotest AG, Landsteinerstr. 5, 63303 Dreieich For enquiries, please contact: Head of IR/Marketing Services Hubert Bötsch Tel. +49 6103 801-444 Fax +49 6103 801-880 E-Mail: hubert_boetsch@biotest.de end of message, (c)DGAP 08.07.2004 ——————————————————————————– WKN: 522720; ISIN: DE0005227201; Index: Listed: Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg und Stuttgart 081556 Jul 04